This article is more than 5 years old. Information may no longer be current.

Tanabe to commercialize, market valganciclovir in Japan

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

OSAKA, Japan — Tanabe Seiyaku will market a drug for the treatment of cytomegalovirus retinitis in Japan, once regulatory approval has been granted, the company announced here in a press release. Tanabe has secured Japanese marketing rights to the drug from Switzerland’s Roche.

Valganciclovir, marketed outside Japan as Valcyte, was introduced in 2001 for the treatment of CMV retinitis in AIDS patients. The drug is also indicated for the treatment of CMV infections in transplant patients.

Tanabe already markets another Roche drug, ganciclovir. Valganciclovir, the prodrug of ganciclovir, has a bioavailability about 10 times higher, according to the press release from Tanabe.